Drug Profile
Research programme: ERRa-inhibitor based breast cancer therapeutics - Lead Pharma
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Lead Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action ERRalpha estrogen-related receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in Netherlands (PO)
- 21 Nov 2017 Research programme: breast cancer therapeutics - Lead Pharma is available for licensing as of 21 Nov 2017. http://www.leadpharma.com/
- 21 Nov 2017 Preclinical trials in Triple negative Breast cancer in Netherlands (PO)